Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Russia submits COVID-19 vaccine to WHO for emergency use listing

Russia became first country to grant approval to a COVID-19 vaccine in August

- PMLiVE

UK Vaccine Taskforce chief says first COVID-19 vaccines ‘likely to be imperfect’

Taskforce has so far secured access to six potential COVID-19 vaccines

- PMLiVE

The science of the deal

Business development is more like child-raising than you might think

- PMLiVE

Celebrating the hard work and dedication of our wonderful Talent Manager

For those who follow Porterhouse Medical Group on social media and keep an eye on the News & Views section of our website, you will be aware that we have...

Porterhouse Medical Group

- PMLiVE

Keytruda growth helps Merck to offset COVID-19 impact in Q3

Profits beat expectations in the third quarter of 2020

- PMLiVE

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

Data monitoring committee has not yet conducted any interim efficacy analysis of the shot

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

- PMLiVE

Warren Buffett’s greatest health lesson

He told us about it almost two decades ago – we didn’t pay attention

- PMLiVE

COVID-19 vaccine developers won’t face pre-approval FDA inspections for EUAs

Companies typically face inspections before gaining approval from the FDA

- PMLiVE

Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

- PMLiVE

Researchers say COVID-19 antibody levels have fallen rapidly in the UK

Number of people testing positive for antibodies fell by 26.5% between June and September

- PMLiVE

Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

Bamlanivimab is being studied in a number of additional ongoing trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links